A Phase 4 interventional study of Placebo and Amoxicillin in Community-acquired Pneumonia, sponsored by Jeffrey. Recruiting at 1 site in Canada. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2024-12-12.
Sponsored by Jeffrey · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Community-Acquired Pneumonia with a site in Canada — 7 open to participants now, 7 under way, 4 of them phase 3. Community-Acquired Pneumonia · Canada.
Among the 15 studies in Community-Acquired Pneumonia with a site in Canada, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 4, and was the 13th registered.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.
Browse Community-Acquired Pneumonia studies →7 of the 15 studies in Community-Acquired Pneumonia with a site in Canada are open now. Recruiting first, the newest first:
Jeffrey Pernica · Sites in Canada
Ages 6 mo–18 yrs
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
Jeffrey Pernica · Sites in Canada
Ages 6 mo–18 yrs
University of Manitoba · Sites in Canada, United States, Brazil and 1 more country
Ages 18+
St. Justine's Hospital · Sites in Canada
Ages 3 mo–18 yrs · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: 6 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4 · Phase 4 3
First in 2001; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.
Median enrollment 219 across the 11 interventional studies, 1,082 across the 4 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 15 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jeffrey as lead sponsor.
Jeffrey has 1 study filed under Community-Acquired Pneumonia — fewer than ten, so there is no comparison to draw.
3 of the studies in Community-Acquired Pneumonia with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710080Phase 3Ottawa Heart Institute Research CorporationTargeting Vascular INflammation in Patients With Community-Acquired Pneumonia | 2026-12-31 |
| NCT03031210Phase 3St. Justine's HospitalTwice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia. | 2027-06-01 |
| NCT06114888Jeffrey PernicaOptimizing Care for Children Hospitalized With Community-acquired Pneumonia: Novel Diagnostics | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Community-Acquired Pneumonia with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Children are commonly hospitalized because of community-acquired pneumonia (CAP). There are multiple high-quality randomized trials of short-course antibiotic therapy (3-5 days of treatment) for adults hospitalized with CAP - but there is very little evidence in children. We intend to do a pilot RCT of short-course (3-5 days) vs standard-duration (8-10 days) antibiotic therapy for children hospitalized for CAP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
children with a history of fever who are hospitalized with CAP (ie. 'severe CAP') as per the clinical team and who have abnormal chest imaging (eg. radiograph, ultrasound) will be eligible. They must also have at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 days of placebo (after participants already received 3-5 days of antibiotics)
Drug: Placebo
5 days of amoxicillin (after participants already received 3-5 days of antibiotics)
Drug: Amoxicillin
5 days of placebo to be given after 3-5 days of antibiotics
Standard-dose amoxicillin (approved by Health Canada) to be given x 5 days.
Consent success
The proportion of potentially eligible participants who consent
Time frame: Day 0
Open-label antibiotic use
The proportion of participants who receive open-label (non-study) antibiotics
Time frame: before Day 30
Losses to followup
The proportion of participants lost to follow-up
Time frame: before Day 30
Proportion of participants with late clinical response
LCR is defined as: i) clinical improvement in fever, work of breathing, oral intake, and activity level, AND ii) lack of receipt of additional antimicrobials
Time frame: Day 15
Proportion of participants with repeat hospitalization for CAP
Time frame: before Day 30
Proportion of participants with drug-related AEs (any severity)
Time frame: before Day 30
Proportion of participants with serious drug AEs
Time frame: before Day 30
Proportion of participants with unscheduled ED or urgent care visits
Time frame: before Day 30
Proportion of participants with unscheduled primary care visits
Time frame: before Day 30
Proportion of participants who develop complicated pneumonia
Complicated defined by effusion, empyaema, necrotizing pneumonia
Time frame: before Day 30
Started Apr 2024 (actual). Primary completion is estimated for Nov 2025, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Community-Acquired Pneumonia →